Anna Orlova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/536085/publications.pdf

Version: 2024-02-01

219	7,908	46918 47	74018 75
papers	citations	h-index	g-index

221	221	221	4455
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase I Trial of ^{99m}Tc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer. Journal of Nuclear Medicine, 2022, 63, 528-535.	2.8	29
2	Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts. Journal of Nuclear Medicine, 2022, 63, 1046-1051.	2.8	9
3	Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2. Pharmaceutics, 2022, 14, 522.	2.0	2
4	Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands. Pharmaceutics, 2022, 14, 1098.	2.0	8
5	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. Biomedicines, 2022, 10, 1293.	1.4	2
6	Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. Pharmaceutics, 2022, 14, 1092.	2.0	5
7	Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. Pharmaceutics, 2022, 14, 1475.	2.0	4
8	Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle. Biomaterials, 2021, 266, 120381.	5.7	11
9	Phase I Study of ^{99m}Tc-ADAPT6, a Scaffold Proteinâ€“Based Probe for Visualization of HER2 Expression in Breast Cancer. Journal of Nuclear Medicine, 2021, 62, 493-499.	2.8	41
10	Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer. Pharmaceutics, 2021, 13, 182.	2.0	7
11	Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting. Cancers, 2021, 13, 500.	1.7	12
12	66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26. Scientific Reports, 2021, 11, 3631.	1.6	10
13	The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule. Pharmaceutics, 2021, 13, 292.	2.0	10
14	Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. International Journal of Molecular Sciences, 2021, 22, 2770.	1.8	14
15	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. Pharmaceutics, 2021, 13, 430.	2.0	8
16	Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. Bulletin of Siberian Medicine, 2021, 20, 23-30.	0.1	6
17	PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology. International Journal of Molecular Sciences, 2021, 22, 3663.	1.8	18
18	Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused AffibodyÂ® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain. Pharmaceutics, 2021, 13, 839.	2.0	5

#	Article	IF	Citations
19	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1. Cancers, 2021, 13, 3589.	1.7	7
20	The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. Seminars in Cancer Biology, 2021, 72, 185-197.	4.3	27
21	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. Cancers, 2021, 13, 3939.	1.7	8
22	HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. Cancers, 2021, 13, 4791.	1.7	6
23	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. Cancers, 2021, 13, 85.	1.7	16
24	A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers. Applied Materials Today, 2021, 25, 101199.	2.3	17
25	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics, 2021, 13, 1847.	2.0	4
26	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. Pharmaceutics, 2021, 13, 1974.	2.0	6
27	Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. Cancers, 2021, 13, 6181.	1.7	1
28	Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. International Journal of Biological Macromolecules, 2020, 145, 216-225.	3.6	20
29	Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1. Molecules, 2020, 25, 4719.	1.7	11
30	Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer. Pharmaceutics, 2020, 12, 977.	2.0	8
31	Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancerâ€"Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. Pharmaceutics, 2020, 12, 614.	2.0	19
32	Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches. Scientific Reports, 2020, 10, 18148.	1.6	5
33	Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting. Scientific Reports, 2020, 10, 20777.	1.6	12
34	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. Molecules, 2020, 25, 5993.	1.7	6
35	Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1. International Journal of Molecular Sciences, 2020, 21, 3310.	1.8	17
36	Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. Pharmaceutics, 2020, 12, 551.	2.0	9

#	Article	IF	Citations
37	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. International Journal of Molecular Sciences, 2020, 21, 1972.	1.8	9
38	Affibody Molecules as Targeting Vectors for PET Imaging. Cancers, 2020, 12, 651.	1.7	56
39	Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. International Journal of Molecular Sciences, 2020, 21, 1312.	1.8	7
40	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. Pharmaceutics, 2020, 12, 391.	2.0	7
41	Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 16.	1.8	38
42	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. Current Medicinal Chemistry, 2020, 27, 7090-7111.	1.2	9
43	Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart. Pharmaceutics, 2019, 11, 380.	2.0	6
44	Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibodyâ€“DM1 Drug Conjugates. Cancers, 2019, 11, 1168.	1.7	12
45	Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. Pharmaceutics, 2019, 11, 358.	2.0	17
46	Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3. Scientific Reports, 2019, 9, 9405.	1.6	34
47	Potent and specific fusion toxins consisting of a HER2â€‘binding, ABDâ€‘derived affinity protein, fused to truncated versions of Pseudomonas exotoxinï¿½A. International Journal of Oncology, 2019, 55, 309-319.	1.4	10
48	Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. Cancers, 2019, 11, 1371.	1.7	26
49	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. Scientific Reports, 2019, 9, 655.	1.6	18
50	Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging. International Journal of Molecular Sciences, 2019, 20, 3047.	1.8	18
51	Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 140, 109-120.	2.0	21
52	Trastuzumab cotreatment improves survival of mice with PCâ€ƀ prostate cancer xenografts treated with the GRPR antagonist ¹⁷⁷Luâ€ĐOTAGAâ€ŦEG₂â€ŘM26. International Journal of Cancer, 2019, 145, 3347-3358.	2.3	30
53	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. Scientific Reports, 2019, 9, 6779.	1.6	8
54	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. Biomaterials, 2019, 203, 73-85.	5.7	19

#	Article	IF	Citations
55	Comparison of tumorâ€'targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2. International Journal of Oncology, 2019, 54, 1209-1220.	1.4	19
56	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers. International Journal of Molecular Sciences, 2019, 20, 1080.	1.8	21
57	The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis. Haematologica, 2019, 104, 1907-1909.	1.7	13
58	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. Scientific Reports, 2019, 9, 17086.	1.6	14
59	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. Scientific Reports, 2019, 9, 14907.	1.6	14
60	Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. Scientific Reports, 2019, 9, 17710.	1.6	14
61	Direct Targeting Options for STAT3 and STAT5 in Cancer. Cancers, 2019, 11, 1930.	1.7	65
62	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 134, 37-48.	2.0	21
63	Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. Molecular Pharmaceutics, 2019, 16, 995-1008.	2.3	35
64	Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe. Scientific Reports, 2018, 8, 2998.	1.6	22
65	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acidâ€"Mediated Pretargeting: In Vivo Proof of Principle. Journal of Nuclear Medicine, 2018, 59, 1092-1098.	2.8	48
66	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia, 2018, 32, 1135-1146.	3.3	112
67	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules. Amino Acids, 2018, 50, 981-994.	1.2	16
68	Molecular design of radiocopper-labelled Affibody molecules. Scientific Reports, 2018, 8, 6542.	1.6	13
69	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. Journal of Nuclear Medicine, 2018, 59, 885-891.	2.8	101
70	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. Journal of Nuclear Medicine, 2018, 59, 93-99.	2.8	29
71	Cyclic versus Noncyclic Chelating Scaffold for ⁸⁹Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. Molecular Pharmaceutics, 2018, 15, 175-185.	2.3	31
72	Affibodyâ€'mediated imaging of EGFR expression in prostate cancer using radiocobaltâ€'labeled DOTAâ€'ZEGFR:2377. Oncology Reports, 2018, 41, 534-542.	1.2	4

#	Article	IF	Citations
73	Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. Cells, 2018, 7, 141.	1.8	21
74	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. Theranostics, 2018, 8, 4462-4476.	4.6	25
75	Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. Cells, 2018, 7, 164.	1.8	19
76	Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. Journal of Controlled Release, 2018, 288, 84-95.	4.8	40
77	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. Scientific Reports, 2018, 8, 9643.	1.6	11
78	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. Contrast Media and Molecular Imaging, 2018, 2018, 1-11.	0.4	30
79	Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. Molecular Pharmaceutics, 2018, 15, 3394-3403.	2.3	19
80	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with ¹¹¹In and ⁶⁸Ga. Molecular Pharmaceutics, 2018, 15, 2674-2683.	2.3	15
81	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. Scientific Reports, 2017, 7, 43118.	1.6	20
82	The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule. Scientific Reports, 2017, 7, 5961.	1.6	29
83	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. Scientific Reports, 2017, 7, 14780.	1.6	17
84	Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with ⁶⁴Cu Using NOTA and NODAGA. Contrast Media and Molecular Imaging, 2017, 2017, 1-12.	0.4	14
85	High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. Contrast Media and Molecular Imaging, 2017, 2017, 1-10.	0.4	27
86	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. International Journal of Oncology, 2017, 51, 1765-1774.	1.4	10
87	Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors. Theranostics, 2016, 6, 93-103.	4.6	53
88	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸Ga]ABY-025 Affibody PET/CT. Theranostics, 2016, 6, 262-271.	4.6	204
89	PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. International Journal of Oncology, 2016, 48, 1325-1332.	1.4	50
90	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule ⁶⁸Ga-ABY-025 in Breast Cancer Patients. Journal of Nuclear Medicine, 2016, 57, 867-871.	2.8	88

#	Article	IF	Citations
91	Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin. International Journal of Oncology, 2016, 49, 1185-1194.	1.4	24
92	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. Molecular Pharmaceutics, 2016, 13, 3676-3687.	2.3	30
93	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. International Journal of Oncology, 2016, 49, 2285-2293.	1.4	27
94	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6. Bioconjugate Chemistry, 2016, 27, 2678-2688.	1.8	13
95	Synthesis of ¹¹Câ€labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [¹¹C]CO. ChemistryOpen, 2016, 5, 566-573.	0.9	16
96	Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins. Bioconjugate Chemistry, 2016, 27, 716-726.	1.8	38
97	Feasibility of Affibody-Based Bioorthogonal Chemistryâ€“Mediated Radionuclide Pretargeting. Journal of Nuclear Medicine, 2016, 57, 431-436.	2.8	46
98	Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. International Journal of Oncology, 2016, 48, 2124-2134.	1.4	29
99	Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. Molecular Pharmaceutics, 2016, 13, 1668-1678.	2.3	33
100	Affibody-mediated PET imaging of HER3 expression in malignant tumours. Scientific Reports, 2015, 5, 15226.	1.6	56
101	Siteâ€Specific Radioiodination of HER2â€Targeting Affibody Molecules using 4â€Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity. ChemistryOpen, 2015, 4, 174-182.	0.9	12
102	Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. Oncology Reports, 2015, 34, 1042-1048.	1.2	30
103	Evaluation of 99mTc-ZIGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. Amino Acids, 2015, 47, 303-315.	1.2	22
104	The effect of macrocyclic chelators on the targeting properties of the 68 Ga-labeled gastrin releasing peptide receptor antagonist PEG 2 -RM26. Nuclear Medicine and Biology, 2015, 42, 446-454.	0.3	46
105	Comparing the measured affinity of 111In-labeled ligands for cellular receptors by monitoring gamma, beta, or X-ray radiation with three different LigandTracerÂ® devices. Journal of Radioanalytical and Nuclear Chemistry, 2015, 304, 823-828.	0.7	4
106	Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients. Oncology Letters, 2015, 9, 950-954.	0.8	6
107	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. Cancer Research, 2015, 75, 4364-4371.	0.4	55
108	The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a 68Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin. Molecules, 2014, 19, 10455-10472.	1.7	55

#	Article	IF	Citations
109	Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. International Journal of Oncology, 2014, 44, 1998-2008.	1.4	14
110	¹⁸⁸Re-Z_{HER2:V2}, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment. Journal of Nuclear Medicine, 2014, 55, 1842-1848.	2.8	23
111	Methods for Radiolabelling of Monoclonal Antibodies. Methods in Molecular Biology, 2014, 1060, 309-330.	0.4	40
112	Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with ¹⁸F-4-Fluorobenzaldehyde. Bioconjugate Chemistry, 2014, 25, 82-92.	1.8	25
113	Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer. Cancer Immunology Research, 2014, 2, 80-90.	1.6	78
114	Gallium-68-Labeled Affibody Molecule for PET Imaging of PDGFRÎ² Expression in Vivo. Molecular Pharmaceutics, 2014, 11, 3957-3964.	2.3	45
115	Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re. European Journal of Medicinal Chemistry, 2014, 87, 519-528.	2.6	19
116	Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1450-1459.	3.3	40
117	Imaging of Platelet-Derived Growth Factor Receptor Î² Expression in Glioblastoma Xenografts Using Affibody Molecule ¹¹¹In-DOTA-Z09591. Journal of Nuclear Medicine, 2014, 55, 294-300.	2.8	50
118	Position for Site-Specific Attachment of a DOTA Chelator to Synthetic Affibody Molecules Has a Different Influence on the Targeting Properties of ⁶⁸ Ga-Compared to ¹¹¹ In-Labeled Conjugates. Molecular Imaging, 2014, 13, 7290.2014.00034.	0.7	12
119	In vitro modeling of HER2-targeting therapy in disseminated prostate cancer. International Journal of Oncology, 2014, 45, 2153-2158.	1.4	8
120	Histidine-Rich Glycoprotein Uptake and Turnover Is Mediated by Mononuclear Phagocytes. PLoS ONE, 2014, 9, e107483.	1.1	17
121	Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine. Current Pharmaceutical Design, 2014, 20, 2275-2292.	0.9	14
122	Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. Biochemical and Biophysical Research Communications, 2013, 441, 820-824.	1.0	11
123	Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Moleculeâ€“Albumin-Binding Domain Fusion Protein. Journal of Nuclear Medicine, 2013, 54, 961-968.	2.8	75
124	Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging. Nuclear Medicine and Biology, 2013, 40, 378-386.	0.3	15
125	[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 439-449.	3.3	38
126	In Vivo and In Vitro Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 187-195.	0.7	30

#	Article	IF	Citations
127	HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [^{99m}Tc(CO)₃]⁺-Labeled Affibody Molecules. Journal of Medicinal Chemistry, 2013, 56, 4966-4974.	2.9	54
128	Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with ⁶⁸Ga and ¹¹¹In via Maleimido Derivatives of DOTA and NODAGA. Bioconjugate Chemistry, 2013, 24, 1102-1109.	1.8	43
129	Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging. Bioconjugate Chemistry, 2013, 24, 1144-1153.	1.8	62
130	Influence of Macrocyclic Chelators on the Targeting Properties of 68Ga-Labeled Synthetic Affibody Molecules: Comparison with 111In-Labeled Counterparts. PLoS ONE, 2013, 8, e70028.	1.1	50
131	In Vitro and In Vivo Evaluation of a 18F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging. PLoS ONE, 2013, 8, e81932.	1.1	44
132	Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification. PLoS ONE, 2013, 8, e62791.	1.1	61
133	Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule ¹¹¹In-DOTA-Z_{IGF1R:4551}. Journal of Nuclear Medicine, 2012, 53, 90-97.	2.8	44
134	Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition. Journal of Nuclear Medicine, 2012, 53, 953-960.	2.8	72
135	Influence of DOTA Chelator Position on Biodistribution and Targeting Properties of ¹¹¹In-Labeled Synthetic Anti-HER2 Affibody Molecules. Bioconjugate Chemistry, 2012, 23, 1661-1670.	1.8	34
136	Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA. Nuclear Medicine and Biology, 2012, 39, 518-529.	0.3	15
137	Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discovery Today, 2012, 17, 1224-1232.	3.2	64
138	Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. Tumor Biology, 2012, 33, 641-651.	0.8	21
139	Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 693-702.	3.3	11
140	Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules. Amino Acids, 2012, 42, 1975-1985.	1.2	16
141	Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 481-492.	3.3	40
142	Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules. Bioconjugate Chemistry, 2011, 22, 894-902.	1.8	25
143	Use of a HEHEHE Purification Tag Instead of a Hexahistidine Tag Improves Biodistribution of Affibody Molecules Site-Specifically Labeled with ^{99m}Tc, ¹¹¹In, and ¹²⁵I. Journal of Medicinal Chemistry, 2011, 54, 3817-3826.	2.9	53
144	Influence of an aliphatic linker between DOTA and synthetic ZHER2:342 Affibody molecule on targeting properties of the 111In-labeled conjugate. Nuclear Medicine and Biology, 2011, 38, 697-706.	0.3	8

#	Article	IF	Citations
145	Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody. Nuclear Medicine and Biology, 2011, 38, 1093-1102.	0.3	28
146	Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [111In]-labeled CHX-Aâ€³DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. Experimental and Therapeutic Medicine, 2011, 2, 523-528.	0.8	22
147	Imaging agents for in vivo molecular profiling of disseminated prostate cancer - targeting EGFR receptors in prostate cancer: Comparison of cellular processing of [111In]-labeled affibody molecule ZEGFR:2377 and cetuximab. International Journal of Oncology, 2011, 38, 1137-43.	1.4	13
148	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. International Journal of Oncology, 2011, 40, 1677-82.	1.4	20
149	Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 531-539.	3.3	46
150	Molecular Design and Optimization of ^{99m}Tc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties. Journal of Nuclear Medicine, 2011, 52, 461-469.	2.8	80
151	Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. International Journal of Oncology, 2010, 36, 757-63.	1.4	49
152	186Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 260-269.	3.3	41
153	Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 613-622.	3.3	103
154	A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1356-1367.	3.3	75
155	Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors. Molecular Imaging and Biology, 2010, 12, 54-62.	1.3	33
156	Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic ¹¹¹In- or ⁶⁸Ga-Labeled Affibody Molecules. Journal of Nuclear Medicine, 2010, 51, 892-897.	2.8	271
157	Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. Human Antibodies, 2010, 19, 107-111.	0.6	10
158	Influence of Labelling Methods on Biodistribution and Imaging Properties of Radiolabelled Peptides for Visualisation of Molecular Therapeutic Targets. Current Medicinal Chemistry, 2010, 17, 2636-2655.	1.2	63
159	HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [^{99m}Tc(CO)₃]⁺, and Shows Improved Biodistribution with Reduced Hepatic Radioactivity Accumulation. Bioconjugate Chemistry, 2010, 21, 2013-2022.	1.8	72
160	Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncology, The, 2010, 11, 992-1000.	5.1	91
161	Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold. Journal of Nuclear Medicine, 2010, 51, 1131-1138.	2.8	81
162	Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry. Journal of Nuclear Medicine, 2009, 50, 274-283.	2.8	98

#	Article	IF	Citations
163	Synthesis and chemoselective intramolecular crosslinking of a HER2â€binding affibody. Biopolymers, 2009, 92, 116-123.	1.2	14
164	Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 692-701.	3.3	54
165	The influence of Bz-DOTA and CHX-Aâ€³-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1460-1468.	3.3	27
166	Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1864-1873.	3.3	43
167	Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3912-3914.	1.0	17
168	On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a ¹²⁴I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model. Journal of Nuclear Medicine, 2009, 50, 417-425.	2.8	131
169	Targeting of HER2-Expressing Tumors with a Site-Specifically ^{99m}Tc-Labeled Recombinant Affibody Molecule, Z_{HER2:2395}, with C-Terminally Engineered Cysteine. Journal of Nuclear Medicine, 2009, 50, 781-789.	2.8	97
170	Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2245-2255.	3.3	69
171	Directed Evolution to Low Nanomolar Affinity of a Tumor-Targeting Epidermal Growth Factor Receptor-Binding Affibody Molecule. Journal of Molecular Biology, 2008, 376, 1388-1402.	2.0	138
172	Slow Internalization of Anti-HER2 Synthetic Affibody Monomer¹¹¹In-DOTA-Z_{HER2:342-pep2}: Implications for Development of Labeled Tracers. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 435-442.	0.7	108
173	Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of ^{99m}Tc-Labeled Anti-HER2 Affibody Molecules. Bioconjugate Chemistry, 2008, 19, 2568-2576.	1.8	44
174	Evaluation of Maleimide Derivative of DOTA for Site-Specific Labeling of Recombinant Affibody Molecules. Bioconjugate Chemistry, 2008, 19, 235-243.	1.8	83
175	Evaluation of a Maleimido Derivative of CHX-Aâ€²â€² DTPA for Site-Specific Labeling of Affibody Molecules. Bioconjugate Chemistry, 2008, 19, 1579-1587.	1.8	35
176	Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors. Cancer Research, 2007, 67, 2178-2186.	0.4	176
177	Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. International Journal of Molecular Medicine, 2007, 19, 285.	1.8	14
178	Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule. Cancer Research, 2007, 67, 2773-2782.	0.4	203
179	In VivoEvaluation of Cysteine-Based Chelators for Attachment of99mTc to Tumor-Targeting Affibody Molecules. Bioconjugate Chemistry, 2007, 18, 549-558.	1.8	53
180	^{99m}Tc-maEEE-Z_{HER2:342}, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors. Bioconjugate Chemistry, 2007, 18, 1956-1964.	1.8	98

#	Article	IF	Citations
181	Update: Affibody Molecules for Molecular Imaging and Therapy for Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 573-584.	0.7	58
182	Affibody molecules: potential forin vivoimaging of molecular targets for cancer therapy. Expert Opinion on Biological Therapy, 2007, 7, 555-568.	1.4	117
183	Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 722-733.	3.3	84
184	99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1843-1853.	3.3	79
185	Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. International Journal of Molecular Medicine, 2007, 19, 285-91.	1.8	26
186	Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. International Journal of Molecular Medicine, 2007, 19, 485-93.	1.8	8
187	Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. International Journal of Molecular Medicine, 2007, 20, 397-404.	1.8	21
188	Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 631-638.	3.3	64
189	Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule. Cancer Research, 2006, 66, 4339-4348.	0.4	462
190	Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. Journal of Nuclear Medicine, 2006, 47, 512-9.	2.8	65
191	Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI). Anticancer Research, 2006, 26, 1217-23.	0.5	10
192	111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. Journal of Nuclear Medicine, 2006, 47, 846-53.	2.8	72
193	Evaluation of ((4-Hydroxyphenyl)ethyl)maleimide for Site-Specific Radiobromination of Anti-HER2 Affibody. Bioconjugate Chemistry, 2005, 16, 1547-1555.	1.8	49
194	In Vitro Characterization of 211At-Labeled Antibody A33â€"a Potential Therapeutic Agent Against Metastatic Colorectal Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 514-523.	0.7	11
195	An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay. International Journal of Oncology, 2005, 27, 1355.	1.4	0
196	Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. Nuclear Medicine and Biology, 2005, 32, 613-622.	0.3	24
197	[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. Oncology Reports, 2005, 13, 1169-75.	1.2	10
198	Targeting of a Head and Neck Squamous Cell Carcinoma Xenograft Model Using the Chimeric Monoclonal Antibody U36 Radioiodinated with a closo-Dodecaborate-containing Linker. Acta Oto-Laryngologica, 2004, 124, 1078-1085.	0.3	6

#	Article	IF	Citations
199	[177Lu]Bz-DTPA-EGF: Preclinical Characterization of a Potential Radionuclide Targeting Agent Against Glioma. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 195-204.	0.7	12
200	Comparative Biodistribution of Potential Anti- Glioblastoma Conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in Normal Mice. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 491-502.	0.7	12
201	Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB11H11. Aspects of labelling chemistry in aqueous solution using Chloramine-T. Radiochimica Acta, 2004, 92, 311-315.	0.5	2
202	Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media. Journal of Radioanalytical and Nuclear Chemistry, 2004, 260, 295-299.	0.7	5
203	Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives. European Journal of Organic Chemistry, 2004, 2004, 3719-3725.	1.2	5
204	Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [¹¹¹In]DTPA-hEGF and [¹¹¹In]Bz-DTPA-hEGF in Normal Mice. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 491-501.	0.7	13
205	Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells. Anticancer Research, 2004, 24, 4035-41.	0.5	8
206	Title is missing!. Journal of Radioanalytical and Nuclear Chemistry, 2003, 256, 67-71.	0.7	5
207	Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211 At-EGF. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1348-1356.	3.3	26
208	[111In]Bz-DTPA-hEGF: Preparation andIn VitroCharacterization of a Potential Anti-Glioblastoma Targeting Agent. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 643-654.	0.7	16
209	Approaches to Improve Cellular Retention of Radiohalogen Labels Delivered by Internalising Tumour-Targeting Proteins and Peptides. Current Medicinal Chemistry, 2003, 10, 2447-2460.	1.2	40
210	Comparative Biodistribution of the Radiohalogenated (Br, I and At) Antibody A33. Implications for In Vivo Dosimetry.. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 385-396.	0.7	14
211	Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma localizing agent. Journal of Radioanalytical and Nuclear Chemistry, 2002, 251, 409-412.	0.7	2
212	Closo-dodecaborate (2-) anion as a potential prosthetic group for attachment of astatine to proteins. Aspects of the labelling chemistry with chloramine-T. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 251-260.	0.5	18
213	Title is missing!. Journal of Radioanalytical and Nuclear Chemistry, 2000, 246, 207-213.	0.7	5
214	Cellular processing of 125I- and 111in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nuclear Medicine and Biology, 2000, 27, 827-835.	0.3	36
215	Optimized indirect 76br-bromination of antibodies using n-succinimidyl para-[76br]bromobenzoate for radioimmuno PET. Nuclear Medicine and Biology, 2000, 27, 837-843.	0.3	22
216	Closo-Dodecaborate(2-) as a Linker for Iodination of Macromolecules. Aspects on Conjugation Chemistry and Biodistribution. Bioconjugate Chemistry, 1999, 10, 338-345.	1.8	34

#	Article	IF	Citations
217	[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: Preparation and pre-clinical evaluation. Oncology Reports, 0, , .	1.2	2
218	Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated. Oncology Reports, 0, , .	1.2	2
219	Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. International Journal of Molecular Medicine, 0, , .	1.8	6